Crystal structure of Escherichia coli type I signal peptidase P84A in complex with lipopeptide antibiotic arylomycin A2
Journal of Structural Biology · 2025
DOI: 10.1016/j.jsb.2025.108260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Structural Biology, 2025. Verfasst von Chuanyun Luo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Biochemistry, Simon Fraser University, South Science Building 8888 University Drive, Burnaby, British Columbia V5…. Hauptthemen laut MEDLINE: Escherichia coli, Anti-Bacterial Agents, Serine Endopeptidases, Membrane Proteins. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Government of Saskatchewan, National Research Council Canada.
Abstract (Originalsprache)
Type I signal peptidase (SPase I) is an essential membrane-bound enzyme that removes amino-terminal signal peptides from secretory proteins. Owing to its critical role in bacterial viability and its periplasmic accessibility, SPase I has emerged as an attractive target for antibiotic development. Arylomycins, a class of macrocyclic lipohexapeptide natural products, inhibit SPase I by binding to its active site. Previous studies have identified a key resistance determinant-a proline residue at the base of the substrate-binding groove (Pro84 inEscherichia coliSPase I)-which reduces arylomycin affinity. Here, we present the crystal structure of theE. coliSPase I P84A mutant in complex with arylomycin A2, revealing that the introduced alanine enables an additional hydrogen bond between the enzyme backbone and the arylomycin N-terminal carbonyl, thus enhancing the affinity for arylomycins. Furthermore, a newly developed preprotein-binding assay utilizing a non-cleavable version of ProOmpA Nuclease A demonstrates that substituting SPase I Pro84 with serine or leucine disrupts substrate recognition, underscoring the delicate balance between inhibitor resistance and substrate processing. These findings reveal that residue Pro84 participates in the interaction between preprotein signal peptides and the E. coli SPase I substrate-binding groove, offering a foundation for designing next-generation arylomycin analogs with improved antibacterial potency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Biochemistry, Simon Fraser University, South Science Building 8888 University Drive, Burnaby, British Columbia V5A 1S6 Canada.
- Department of Molecular Biology and Biochemistry, Simon Fraser University, South Science Building 8888 University Drive, Burnaby, British Columbia V5A 1S6 Canada. Electronic address: mpaetzel@sfu.ca.
Förderung
- Canadian Institutes of Health Research
- Government of Saskatchewan
- National Research Council Canada
- Natural Sciences and Engineering Research Council of Canada
- University of Saskatchewan
- Canada Foundation for Innovation
- National Research Council
Zitieren
APA
Luo, C., & Paetzel, M. (2025). Crystal structure of Escherichia coli type I signal peptidase P84A in complex with lipopeptide antibiotic arylomycin A2. Journal of Structural Biology. https://doi.org/10.1016/j.jsb.2025.108260
Vancouver
Luo C, Paetzel M. Crystal structure of Escherichia coli type I signal peptidase P84A in complex with lipopeptide antibiotic arylomycin A2. Journal of Structural Biology. 2025. doi:10.1016/j.jsb.2025.108260
BibTeX
@article{Luo2025,
author = {Luo, Chuanyun and Paetzel, Mark},
title = {Crystal structure of Escherichia coli type I signal peptidase P84A in complex with lipopeptide antibiotic arylomycin A2},
journal = {Journal of Structural Biology},
year = {2025},
doi = {10.1016/j.jsb.2025.108260}
}
EUVIMED